MedTrace Logo

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

NCT03959371 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 620

Last updated 2019-05-22

No results posted yet for this study

Summary

The RUXOREL-MF observational study includes patients with primary and post-essential thrombocythemia/post-polycythemia vera myelofibrosis (MF) being treated with the oral JAK1-/JAK2-inhibitor ruxolitinib in a "real world" setting. Patients are treated according to current indications in Italy (i.e., primary and secondary MF patients with intermediate-1, intermediate-2, and high risk IPSS (International Prognostic Scoring System) scores and symptomatic splenomegaly and/or systemic symptoms). Patients are treated at facilities pertaining to the regional Hematology Network of Lombardy (Rete Ematologica Lombarda) in Italy. Efficacy data, data related to infectious and vascular events, data related to second primary malignancies, data regarding disease progression/transformation, and molecular information in relationship to ruxolitinib treatment will be collected and analyzed.

Conditions

Interventions

DRUG

Ruxolitinib

Observational study including patients with myelofibrosis being treated with ruxolitinib in a "real world" setting. Patients are treated according to current indications.

Sponsors & Collaborators

  • Margherita Maffioli

    lead OTHER

Principal Investigators

  • Francesco Passamonti, MD · Ospedale di Circolo ASST Sette Laghi, Università dell'Insubria, Varese, Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-11
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959371 on ClinicalTrials.gov